friday, September 16, 2022
| Agenda | |
|---|---|
| Session 1: Optimizing Cellular Therapy Manufacturing | |
| CAR T Cell Manufacturing in the Academic setting Isabelle Riviere, PhD | |
| Point of Care Cell Manufacturing - Rewards and Challenges Amittha Wickrema, PhD | |
| Session 2: Mechanisms of Resistance and Relapse to Cellular Therapy | |
| Genomic Drivers of Resistance to Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-cell Lymphoma Jonathan Schatz, MD | |
| Developmental trajectories of CAR-driven T cell failure Nathan Singh, MD | |
| Mechanisms of resistance to CD19-targeted CAR T cell therapies Marco Davila, MD, PhD | |
| Session 3: Cellular Therapy in Non-Malignant Diseases | |
| Therapeutic Gene Editing for Sickle Cell Disease Daniel Bauer, MD, PhD | |
| HIV CAR T cells for HIV Cure Studies James L. Riley, PhD | |
| Session 4: Cellular Therapy in Solid Tumors | |
| CAR-T Cells from Bench to Clinical Application Gianpietro Dotti, MD | |
| High-precision, high-throughput cell profiling for autologous cell therapy development Shana Kelley, PhD | |
| Lightening Talks | |
| Two-Stage CD28-Costimulated CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma Yifei Hu, BA | |
| BCL-2 Inhibition Mediates Treg to TH17 Plasticity Rosy Liao | |
| TCR-T cell therapy targeting solid tumors Steven Wolf, PhD | |
| Investigational New Drug (IND) enabling validation of Tri-specific CD19/20/22 CAR T- cells for Point of Care Manufacturing Mahzad Akbarpour, PhD | |
| Janet Rowley Keynote Lecture | |
| Developing cellular therapies against GD2: It doesn’t hurt! Christian Capitini, MD | |
| Jonas Memorial Keynote Lecture | |
| Development of Cancer-Specific TCR Gene Therapy Hans Schreiber, MD, PhD |